Beximco Signs Contract With Mylan for Distribution in Bangladesh
February 24 2020 - 4:38AM
Dow Jones News
By Jaime Llinares Taboada
Beximco Pharmaceuticals Ltd. said Monday that it has signed a
contract for distribution of certain products of Mylan NV in
Bangladesh.
The London-listed company said it will receive the exclusive
rights to launch Mylan's portfolio of monoclonal antibodies to
treat different types of cancers, rheumatoid arthritis, Crohn's
disease, ulcerative colitis and other medical conditions.
The first product to be launched, in the first quarter of 2020,
will be Ogivri, a breast-cancer drug which is biosimilar to
blockbuster drug Herceptin from Roche Holding AG, Beximco said.
Shares at 0900 GMT were up 1.8 pence, or 4.2%, at 45.0
pence.
Write to Jaime Llinares Taboada at jaime.llinares@wsj.com;
@JaimeLlinaresT
(END) Dow Jones Newswires
February 24, 2020 04:23 ET (09:23 GMT)
Copyright (c) 2020 Dow Jones & Company, Inc.
Roche (QX) (USOTC:RHHBY)
Historical Stock Chart
From Mar 2024 to Apr 2024
Roche (QX) (USOTC:RHHBY)
Historical Stock Chart
From Apr 2023 to Apr 2024
